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Aberrant activation of the androgen receptor (AR)
plays a key role during prostate cancer (PCa) devel-
opment and progression to castration-resistant pros-
tate cancer (CR-PCa) after androgen deprivation ther-
apy, the mainstay systemic treatment for PCa. New
strategies to abrogate AR activity and biomarkers that
predict aggressive tumor behavior are essential for
improved therapeutic intervention. PCa tissue mi-
croarrays herein reveal that prostate-associated gene
4 (PAGE4), an X-linked cancer/testis antigen, is highly
up-regulated in the epithelium of preneoplastic le-
sions compared with benign epithelium, but subse-
quently decreases with tumor progression. We show
that AR signaling is attenuated in PAGE4-expressing
cells both in vitro and in vivo, most likely via im-
paired androgen-induced AR nuclear translocation
and subsequently reduced AR protein stabilization
and phosphorylation at serines 81 and 213. Consis-
tently, epithelial PAGE4 protein levels inversely cor-
related with AR activation status in hormone-naive
and CR-PCa clinical specimens. Moreover, PAGE4 im-
paired the development of CR-PCa xenografts, and
strong PAGE4 immunoreactivity independently pre-
dicted favorable patient survival in hormone-naive
PCa. Collectively, these data suggest that dysregulation of
epithelial PAGE4modulates AR signaling, therebypromot-
ing progression to advanced lethal PCa and highlight the
potential value of PAGE4 as a prognostic and therapeutic
target. (Am J Pathol 2012, 181:1443–1454; http://dx.doi.org/
10.1016/j.ajpath.2012.06.040)
Androgens play a key role in regulating prostate cellular
homeostasis1 via the androgen receptor (AR), a ligand-inducible transcription factor whose dysregulation is as-
sociated with the development/progression of prostate
cancer (PCa), the second leading cause of male cancer
death in Western societies.2 On initial diagnosis, 80% to
90% of PCa are androgen-dependent.3 Approximately
90% of patients respond to current first-line androgen
deprivation therapy, however, many patients experience
disease progression and succumb to castration-resistant
PCa (CR-PCa) within 3 years.4,5 Despite low circulating
androgen levels, AR signaling frequently is reactivated in
CR-PCa and plays a key role in disease progression.6,7
AR reactivation may be attributed to AR hypersensitivity,
promiscuous AR activation, local tumoral androgen pro-
duction, and altered recruitment/expression of AR co-
regulators.8 Such cis-acting AR regulators confer pro-
moter specificity of androgen signaling by modulating AR
maturation and posttranslational modification, AR-protein
interactions, histone modification, or local chromatin re-
modeling.9–16 Thus, the AR and regulators thereof remain
therapeutic targets for CR-PCa.
We previously reported up-regulation of prostate-asso-
ciated gene 4 (PAGE4) on exposure of primary prostatic
epithelial and stromal cells to transforming growth factor
.17,18 PAGE4 is a related member of the germ cell-
associated gene cancer/testis antigens (CTAs),19 an X-
linked gene family with restricted expression to germ
cells in normal tissues yet present in tumor cells of di-
verse histologic origin.20 In addition to testis, the six-
membered PAGE subfamily is expressed highly in pla-
centa and at lower levels in normal prostate and uterus.19
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tial expression, CTAs are considered potential tumor-
specific diagnostic and therapeutic targets.21 Although
the biological function of most CTAs including PAGE4 is
unknown, recent studies have shown that PAGE4 and
PAGE5 are highly intrinsically disordered proteins, a
characteristic that favors low affinity but highly specific
interactions.22–24 Consequently, intrinsic disorder is prev-
alent among regulatory and signaling proteins, including
nuclear hormone receptors such as AR.25 This study aimed
to investigate the function of PAGE4 and evaluate its poten-
tial as a diagnostic and/or therapeutic target in PCa.
Materials and Methods
Reagents and Cell Culture
Reagents were from Sigma Aldrich (St. Louis, MO) unless
otherwise specified. -Tubulin was from Santa Cruz Bio-
technology (Santa Cruz, CA), AR (PG-21) and pSer81-AR
were from Millipore (Billerica, MA), pSer213-AR was from
Imgenex Corp. (San Diego, CA), E-tag was from Bethyl
Laboratories (Montgomery, TX), horseradish-peroxidase–
conjugated secondary antibodies were from Promega
(Madison, WI), and Alexa Fluor–labeled secondary antibod-
ies were from Invitrogen (Carlsbad, CA). The proteasome
inhibitor MG132 was from Calbiochem (La Jolla, CA), and
bicalutamide was from Molekula (Munich, Germany). Cell
lines were from ATCC (LGC Standards, Wesel, Germany).
For steroid hormone stimulation, cells were incubated for 16
hours in media supplemented with charcoal-treated bovine
calf serum (Hyclone Laboratories, Logan, UT) before addi-
tion of dihydrotestosterone (DHT), progesterone, dexa-
methasone, or vehicle equivalent at the indicated concen-
tration for the duration stated. For analysis of pSer213-AR,
cells were incubated for 30 hours in media supplemented
with charcoal-treated bovine calf serum before addition of
DHT or insulin-like growth factor-1 (IGF-1), either alone or in
combination for 4 hours.
Plasmids and Generation of PAGE4-
Overexpressing LNCaP Sublines
PAGE4:Etag was described previously,17 other plasmids
were generous gifts: wild-type AR expression vector
(pARO) and androgen-responsive luciferase reporter
(pARE2tataLuc; Guido Jenster, Rotterdam, The Nether-
lands). Glucocorticoid receptor (GR) alpha expression
vector  expression vector (pGR), glucocorticoid-re-
sponsive luciferase reporter (pGREtkLuc), and pMMTV-
Luc (Stoney Simons Jr, Bethesda, MD). LNCaP and PC3
cells were stably transfected with Sleeping Beauty trans-
posase (SB11) and shuttle transposon (pT2) containing
the PAGE4 open reading frame downstream of the cyto-
megalovirus promoter. Polyclonal lines resistant to 1
g/mL neomycin were selected.PAGE4 Antibody Generation
Synthetic peptides corresponding to residues 45 to 60 of
the PAGE4 amino acid sequence (NP_008934) were cou-
pled to a lysine core generating multiple antigenic peptides
(AltaBioscience, Birmingham, UK). BALB/C mice were im-
munized with 100 g peptide diluted with an equal volume
of Freund’s adjuvant. Once optimal titers were obtained,
mice were surrendered for monoclonal antibody isolation.26
Real-Time Quantitative PCR
RNA isolation, cDNA synthesis, and quantitative PCR
were performed as described.27 Primer sequences are
shown in Table 1. For quantitative PCR, cDNA concen-
trations were normalized to the internal standard hy-
droxymethylbilane synthase, a moderate copy number
housekeeping gene not regulated under the experimen-
tal conditions used. Fold change in gene expression was
determined using the mathematical model ratio 2CT.28
Luciferase Reporter Assays, Transfection, and
siRNA-Mediated Knockdown
Cells seeded in triplicate in 24-well plates in media sup-
plemented with charcoal-treated bovine calf serum were
transfected with firefly luciferase reporter vector (225 ng/
well) and where indicated with 75 ng/well pARO/GR 
expression vector and 400 ng/well PAGE4:Etag using
Lipofectamine 2000 (Invitrogen). pGL4.73, a SV40-driven
renilla luciferase reporter vector (Promega), served as
transfection control. Equal DNA concentrations were
maintained using appropriate empty vectors. Six hours
after transfection, media were exchanged supplemented
Table 1. Primer Sequences
Gene
symbol
Gene
ID Primer sequence*
AR 367 F: 5=-CCTGGCTTCCGCAACTTACAC-3=
R: 5=-GGACCTGTGCATGCGGTACTCA-3=
HMBS 3145 F: 5=-CCAGGACATCTTGGATCTGG-3=
R: 5=-ATGGTAGCCTGCATGGTCTC-3=
IGFBP3 3486 F: 5=-CAAGCGGGAGACAGAATATG-3=
R: 5=-TTATCCACACACCAGCAGAA-3=
KLK3
(PSA)
354 F: 5=-TTGACCCCAAAGAAACTTCA-3=
R: 5=-TGACGTGATACCTTGAAGCA-3=
NKX3-1 4824 F: 5=-GAGACGCTGGCAGAGACC-3=
R: 5=-ATCACCTGAGTGTGGGAGAA-3=
PAGE4 9506 F: 5=-AATGGATCTGGAAAAGACTCG-3=
R: 5=-GTGACATCAGCCATGTGTGTA-3=
RGS2 5997 F: 5=-CCCAAAAGCTGTCCTCAAAA-3=
R: 5=-TTCTGGGCAGTTGTAAAGCA-3=
TAT 6898 F: 5=-CAGGGAGCTCTGAAAAGCAT-3=
R: 5=-CAACGCCCCATAACAGAGAT-3=
TSC22D3
(GILZ)
1831 F: 5=-TGGTGGCCATAGACAACAAG-3=
R: 5=-CAGGGTCTTCAACAGGGTGT-3=
TMPRSS2 7113 F: 5=-GGCTTTGAACTCAGGGTCAC-3=
R: 5=-GGTAGTACTGAGCCGGATGC-3=
*Primer sequences are given 5= to 3=, annealing temperature for all prim-
ers in quantitative PCR is 56°C, and all primers span at least one intron.
F, forward; R, reverse.with the indicated steroid hormone or vehicle equivalent
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Dual-Glo luciferase assay system (Promega) on a Cha-
meleon luminometer (HVD Life Sciences, Vienna, Austria)
and values were normalized to renilla luciferase activity
and total protein content determined by Bradford assay
(Bio-Rad). For knockdown experiments, JEG3 cells were
transfected with scrambled or PAGE4 small-interfering
RNA (siRNA) duplexes (Invitrogen) for 96 hours before pro-
cessing for quantitative PCR or transfection with pGREtkLuc
(for luciferase assays) as described earlier.
Subcellular Fractionation, Western Blotting, and
PSA Determination
Nuclear and cytosolic fractions were prepared using the
NE-PER extraction kit according to the manufacturer’s
instructions (Thermo Fisher Scientific, Vienna, Austria).
Total cell lysates were prepared as described27 and nor-
malized against total protein content via Bradford assay
(Bio-Rad Laboratories, Hercules, CA) before SDS-PAGE,
Western blotting, and densitometric quantification as de-
scribed.27 As specificity control for pSer81- and
pSer213-AR immunoblotting, lysates were incubated with
or without 400 U lambda phosphatase (Cell Signaling
Technology, Danvers, MA) as indicated at 30°C for 30
minutes before SDS-PAGE. Densitometric data were nor-
malized against -actin or total AR (for pSer81-AR and
pSer213-AR) as indicated. Prostate-specific antigen
(PSA) concentration in conditioned media was deter-
mined using the ADVIA Centaur clinical diagnostic PSA
test (Siemens Health Care Diagnostics, Inc., Tarrytown,
NY) and normalized to total protein concentration of the
corresponding cell lysates.
Cell Proliferation
Cell proliferation was determined by WST1 assay (Roche
Applied Science, Indianapolis, IN) as described.29
Xenografts
Six-week-old male athymic mice (Charles River Laborato-
ries, Wilmington, MA) were injected subcutaneously into the
hind flank with 2 106 vector or PAGE4:LNCaP (subline #8)
cells resuspended in 50 L sterile PBS and an equal vol-
ume of Matrigel (BD Biosciences). At the time of inoculation,
mice were either castrated or sham-castrated (each sub-
group, n 17). Harvested tumors were halved, with one half
snap-frozen in liquid nitrogen for RNA isolation and the
second half placed into 4% formaldehyde in PBS for immu-
nohistochemistry (IHC). Experiments were approved by the
Austrian Animal Experimentation Ethics Committee.
Immunofluorescence, IHC, TMA, and
Microscopy
Immunofluorescence was performed as described.29
Use of the clinical samples for tissue microarray (TMA)
construction was approved by the Ethical Committee of
the University of Basel (Switzerland). The PCa progres-sion TMA and scoring system have been described.30,31
Briefly, the arrays were reviewed by an experienced pa-
thologist (L.B.) and the score was calculated by multiply-
ing the given intensity (between 0 and 3) by the percent-
age of cells within this intensity. Thus, a score between 0
and 300 was possible. The advanced PCa TMA com-
prises 305 surgical specimens from palliative transure-
thral resections of the prostate (TURP) from patients with
local advanced obstructive PCa (see Supplemental
Table S1 at http://ajp.amjpathol.org) that typically infiltrate
into the transition zone. Thus, a distinction between pe-
ripheral or transition zone PCa no longer applies, en-
abling direct comparison of epithelial PAGE4 levels in
TURP resections from patients with benign prostatic hy-
perplasia (BPH) (without PCa) versus patients with PCa.
Each specimen is represented by three to four cores. For
PAGE4 analysis, the average value of evaluable spots
per specimen was calculated (denoted as mean PAGE4).
IHC was performed as described.27 Where indicated,
PAGE4 antibodies were pre-incubated overnight at 4°C
in 1% bovine serum albumin/PBS containing 40 g/mL
blocking peptide (residues 45 to 60) or nonblocking pep-
tide corresponding to residues 77 to 92 of the PAGE4 aa
sequence. Sections were counterstained with hematoxy-
lin. Peroxidase-stained TMAs were visualized using a
Zeiss AXIO Imager.A1, using Axio Vision software version
4.6 (Carl Zeiss AG, Feldbach, Switzerland). Peroxidase-
stained xenograft tumor sections were visualized using
an inverted Nikon Eclipse TE300, using Nikon Plan Fluor
ELWD objectives and images acquired using NIS Ele-
ments Basic Research software (Nikon Instruments, Inc.,
Amsterdam, The Netherlands). Fluorescent microscopy
was performed using a confocal laser microscope with
constant laser intensity settings (Zeiss Axiophot, -Ra-
diance scanning system; Carl Zeiss Laser Optics/La-
ser Sharp Software from Bio-Rad).
Statistical Analysis
Numeric data are presented as mean  SEM from at
least three independent experiments. Statistical differ-
ences between treatments were calculated using a
paired Student’s t-test. TMAs were analyzed using the
statistical test indicated using JMP 8.0 software (SAS
Corporation, Cary, NY). For patient survival analyses, the
third quartile of mean epithelial PAGE4 staining intensity
was set as the cut-off with negative/low PAGE4 levels
defined as less than 130 and high PAGE4 levels defined
as 130 or higher. Time point zero for survival statistics was
TURP for local advanced obstructive PCa. P values were
calculated using log-rank tests for univariate analysis and
the Cox proportional hazard model for multivariate analysis.
Results
Dysregulation of Epithelial PAGE4 during
Prostate Cancer Progression
Consistent with previous reports,32 IHC of benign pros-
tate tissue sections using an in-house anti-PAGE4 mono-
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http://ajp.amjpathol.org) revealed intense nucleocytoplas-
mic PAGE4 staining of smooth muscle cells and to a
lesser extent in the stromal cells of the prostate. Either
none or only weak PAGE4 was detectable in endothelial
cells and luminal epithelial cells of benign glands (see
Supplemental Figure S1 at http://ajp.amjpathol.org).
PAGE4 was not detectable in basal epithelial cells. On a
PCa progression TMA, however, high levels of epithelial
PAGE4 were observed in preneoplastic high-grade pros-
tatic intraepithelial neoplasia (PIN) lesions with progres-
sively lower levels in localized PCa and metastases (Fig-
ure 1). In contrast to the nucleocytoplasmic localization of
PAGE4 in benign tissue (see Supplemental Figure S1 at
http://ajp.amjpathol.org), PAGE4 was confined mostly to
the cytoplasm in high-grade PIN and PCa (Figure 1A).
Attenuation of AR and GR Activity in
PAGE4-Positive Cells
Because PAGE4 spatially is restricted to steroidogenic
tissues and aberrant AR signaling is implicated in PCa
development/progression, we investigated whether
Figure 1. Dysregulation of epithelial PAGE4 during prostate cancer devel-
opment and progression. A and B: IHC analysis of PAGE4 on the PCa
progression TMA. Representative images are shown, including a pleural
metastasis (A). B: Mean epithelial PAGE4 staining intensity (SEM) was
quantified as described in Materials and Methods [high-grade PIN (HGPIN)].
All pairwise comparisons were statistically significant (P  0.001) by Wil-
coxon rank sum test.PAGE4 modulates AR activity. In the presence but notabsence of wild-type AR, basal and ligand-induced an-
drogen-responsive luciferase activity was reduced in
PAGE4-expressing COS7 cells (see Supplemental Figure
S3A at http://ajp.amjpathol.org). Similar attenuated activ-
ity was observed for the structurally related GR from a
glucocorticoid-responsive reporter (see Supplemental
Figure S3B at http://ajp.amjpathol.org), but not for the
endogenous progesterone receptor in LNCaP cells (see
Supplemental Figure S3C at http://ajp.amjpathol.org).
In contrast to a recent study,22 we and others ob-
served very low endogenous PAGE4 mRNA levels in
prostate-derived primary cells and PCa cell lines with
PAGE4 undetectable at the protein level (not shown and
G. Jenster, unpublished data). Thus, it was not possible
to perform siRNA-mediated PAGE4 silencing in prostatic
cells. However, consistent with high expression of PAGE
genes in placenta,19 endogenous PAGE4 was readily
detectable in JEG3 (GR) choriocarcinoma cells (Figure
2A), localizing to the nucleocytoplasm (Figure 2B) and
consistent with the earlier-described findings (Figure 1;
see also Supplemental Figure S1 at http://ajp.amjpathol.
org). PAGE4-specific siRNA decreased endogenous
PAGE4 mRNA by 6.3  0.8-fold, markedly reduced
PAGE4 protein levels, and significantly potentiated basal
and ligand-induced activity of a glucocorticoid-respon-
sive luciferase reporter relative to scrambled control
(Figure 2, C–E). Moreover, PAGE4 silencing significantly
potentiated basal expression of the primary glucocorticoid-
responsive genesGILZ, TAT, and RGS2with the expression
ofGILZ and TAT potentiated to levels comparable with those
in dexamethasone-treated scrambled control cells (Figure
2F). In the presence of dexamethasone, PAGE4 knockdown
significantly potentiated dexamethasone-mediated induc-
tion of RGS2 and GILZ (Figure 2F). Similar results were
obtained for a second siRNA targeting a distinct region of
the PAGE4 mRNA transcript (not shown).
Attenuation of Endogenous AR in PAGE4-
Expressing PCa Cells
Subsequent experiments investigated the functional sig-
nificance of increased epithelial PAGE4 in PCa with re-
spect to AR activity using polyclonal LNCaP (AR GR)
sublines overexpressing different levels of native PAGE4
(PAGE4:LNCaP) relative to empty vector control (vector:
LNCaP; Figure 3A). Similar to the earlier description (see
Supplemental Figure S3 at http://ajp.amjpathol.org), basal
and ligand-induced transactivation of endogenous AR
was dose-dependently attenuated in PAGE4:LNCaPs
(Figure 3B), with relative fold induction by DHT (P 
0.0006) also significantly reduced. Although AR mRNA
levels were not altered, expression of the primary andro-
gen-responsive genes PSA, CAV1, and IGFBP3 was re-
duced significantly in PAGE4:LNCaPs but not in parallel-
generated LNCaP sublines overexpressing Dickkopf
homolog 3, a member of the Dickkopf family of wingless-
type MMTV integration site (Wnt) antagonists (see Sup-
plemental Figure S4, A and B, at http://ajp.amjpathol.org),
indicating that these effects are PAGE4-specific and not
an artifact of the overexpression system. Interestingly,
d F: Va
significa
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primary androgen-responsive genes (NKX3-1, TM-
PRSS2; see Supplemental Figure S4A at http://ajp.amj-
pathol.org), suggesting that PAGE4 may exert its effects
in a promoter-specific manner. CAV1 and PSA expres-
sion was investigated further in the presence or absence
of 10 nmol/L DHT (Figure 3C). Relative to vector control,
basal expression and relative fold induction of CAV1 and
PSA by DHTwere attenuated significantly in a PAGE4 dose-
dependent manner (Figure 3C). Similar findings were ob-
served for PSA secretion (Figure 3C).
To investigate whether the androgenic proliferative re-
sponse also was attenuated, vector or PAGE4:LNCaPs
were incubated in the presence or absence of prolifera-
tion-inducing concentrations of DHT (0.1 nmol/L). Rela-
tive to vector control, basal proliferation of PAGE4:
LNCaPs was reduced marginally in sublines 7 and 8
whereas DHT induction of proliferation was attenuated
across all PAGE4:LNCaP sublines in a dose-dependent
manner (Figure 3D). These effects on proliferation appear
to be AR-dependent because stable overexpression of
PAGE4 in AR PC3 PCa cells had no significant effect on
cell proliferation (see Supplemental Figure S4C at http://
Figure 2. Potentiation of endogenous GR activity on PAGE4 knockdown. A
overexpressing LNCaP subline #8 served as positive control (top panel, shor
PAGE4 in JEG3 cells using anti-PAGE4 monoclonal antibody (green) pre-incub
mycin D (7-AAD, red). Merged images are shown (right). Quantitative PCR (C)
scrambled (scr) or PAGE4 siRNA for 72 hours before stimulation with 10 nmol/L
from the glucocorticoid-responsive reporter pGREtkLuc in JEG-3 cells treated a
Values represent mean relative light units (RLU)  SEM of triplicate wells (n 
A, B, and D: Images are representative of three independent experiments. C an
scrambled control from three independent experiments. C, E, and F: Statisticalajp.amjpathol.org). Collectively, these data indicate that ARsignaling is attenuated in both a ligand-dependent and ligand-
independent manner in PAGE4-expressing PCa cells.
Potentiated AR Inhibition by the Clinical AR
Antagonist Bicalutamide in PAGE4-Expressing
PCa Cells
We next compared the level of AR inhibition in PAGE4:
LNCaPs with that achieved by the nonsteroidal anti-an-
drogen bicalutamide by treating vector and PAGE4:
LNCaPs with DHT in the presence or absence of bicalu-
tamide. DHT-mediated induction of PSA served as a mo-
lecular readout for AR activity (Figure 3E). In PAGE4:
LNCaPs treated with DHT alone, PSA mRNA levels were
either comparable with (sublines 7 and 9), or lower than
(subline 8), bicalutamide and DHT combined treated
vector:LNCaPs (Figure 3E). In bicalutamide and DHT
combined treated PAGE4:LNCaP sublines 7 and 9, PSA
mRNA levels were reduced significantly further. Bicalut-
amide had no synergistic effect on PSA expression in
PAGE4:LNCaP#8 (Figure 3E), suggesting that under these
oblotting of endogenous PAGE4 in wild-type (wt) JEG3 cell lysates. PAGE4-
re; middle panel, longer exposure). B: Immunofluorescence of endogenous
or without blocking peptide. Nuclei were counterstained with 7-aminoactino-
rn blotting (D) of endogenous PAGE4 in JEG3 cells transiently transfected with
thasone (DEX) or vehicle equivalent (mock) for 24 hours. E: Luciferase activity
d stimulated with 10 nmol/L DEX () or vehicle equivalent () for 24 hours.
antitative PCR of glucocorticoid-responsive genes in JEG3 cells treated as in C.
lues represent mean fold-change in expression  SEM relative to mock-treated
nce is indicated: NS, not significant where P  0.05, *P  0.05, **P  0.01.: Immun
t exposu
ated with
or Weste
dexame
s in C an
4). F: Quconditions AR inhibition in this subline (which expresses the
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respect to AR-dependent regulation of PSA.
Ligand-Mediated AR Protein Stabilization Is
Attenuated in PAGE4-Expressing PCa Cells
We next sought to investigate the mechanism by which
PAGE4 attenuates AR activity. Subsequent experiments
used PAGE4:LNCaP#8; however, similar findings were
observed for sublines 7 and 9 (not shown). Although
PAGE4 did not alter AR mRNA levels (see Supplemental
Figure S4 at http://ajp.amjpathol.org) or basal AR protein
levels, ligand-mediated AR stabilization was attenuated
in PAGE4:LNCaPs (see Supplemental Figure S5, A and
B, at http://ajp.amjpathol.org). Consistent with previous
reports,33 the proteasome inhibitor MG132 significantly
increased AR protein levels both in the presence and
absence of DHT in vector:LNCaPs. In PAGE4:LNCaPs,
however, MG132 did not rescue suppression of ligand-
induced AR protein stabilization, indicating a protea-
some-independent mechanism. DHT-mediated AR stabi-
lization was investigated further in the presence of
cycloheximide (10 g/mL) to inhibit de novo protein syn-
thesis (see Supplemental Figure S5, C and D, at http://
ajp.amjpathol.org). Compared with vector:LNCaP cells,
AR levels decreased at a faster rate in PAGE4:LNCaPs
(relative t1/2, 2.6  0.3-fold; P  0.05), with significantly
lower AR levels detected at 12 hours (see Supplemental
Figure S5, C and D, at http://ajp.amjpathol.org).Attenuation of AR Phosphorylation in PAGE4-
Expressing PCa Cells
AR phosphorylation at serine (Ser) 81 and Ser213 is
implicated in regulating AR protein stabilization.34–36 In
addition, ligand-mediated AR phosphorylation at Ser81
increases AR chromatin binding and transcriptional ac-
tivity in a promoter-specific manner.34,37–39 Consistent
with the well-documented cross-talk between AR and
IGF1 signaling pathways,40–42 AR phosphorylation at
Ser213 after IGF1-induced AKT activation also is impli-
cated in regulating hormone-binding, AR transcriptional
activity, and is associated with decreased survival of
CR-PCa patients.35,36,43 In accordance with previous ob-
servations,34 DHT increased pAR-Ser81 levels 1.8  0.1-
fold in vector:LNCaPs (Figure 4, A and B). Although basal
levels of pAR-Ser81 were unaltered in PAGE4:LNCaPs
relative to vector control, DHT-mediated induction of
pAR-Ser81 was attenuated (Figure 4, A and B). Similarly,
the synergistic induction of pAR-Ser213 after combined
treatment of vector:LNCaP cells with IGF1 and DHT
(2.1  0.3-fold) was attenuated significantly in PAGE4-
expressing cells (0.9  0.2-fold; P  0.027 relative to
combined treated vector:LNCaPs; Figure 4, C and D).
Ligand-induced AR-Ser81 phosphorylation is tempo-
rally significantly slower than the kinetics of AR nuclear
import.34,44 In addition, pAR-Ser213 appears to be local-
ized predominantly to the nucleus.45 We thus investi-
Figure 3. Attenuation of endogenous AR activity
in PAGE4-expressing PCa cells. A: PAGE4 immu-
noblotting in polyclonal LNCaP sublines stably
overexpressing PAGE4 (#7 to 9) or vector control.
Values denote mean PAGE4 densitometric inten-
sity (SEM) relative to subline 7 normalized
against -actin (n  3). B: Androgen-responsive
luciferase reporter activity (pARE2tataLuc) in vec-
tor and PAGE4:LNCaPs stimulated with 10 nmol/L
DHT or ethanol equivalent (mock) for 24 hours.
Values represent mean relative light units (RLU)
SEM relative to mock-treated vector:LNCaP from
triplicate wells normalized against renilla luciferase
activity and total protein content (n  3). C: Vec-
tor and PAGE4:LNCaPs stimulated with vehicle
(mock) or 10 nmol/L DHT for 24 hours (left and
center) or 72 hours (right) before quantitative
PCR of CAV1 and PSA. Enzyme-linked immu-
nosorbent assay quantification of PSA in 72-hour
conditioned medium (right). Data represent
mean fold-change  SEM relative to mock-
treated vector:LNCaPs (n  4). D: Proliferation
of vector and PAGE4:LNCaPs treated with 0.1
nmol/L DHT or vehicle equivalent (mock) for 24
hours. Mean absorbance  SEM of triplicate
wells is shown (n  3). E: Quantitative PCR of
PSA in vector and PAGE4:LNCaPs preblocked
for 1 hour with 10 mol/L bicalutamide (Bic) or
vehicle equivalent (mock) before stimulation
with 10 nmol/L DHT in the presence or absence
of Bic for 24 hours. Bars represent mean fold-
change in PSA expression (SEM) relative to
DHT-treated vector:LNCaP#1 in the absence of
Bic (n  3). NS, not significant where P  0.05,
*P  0.05, **P  0.01, and ***P  0.001.gated whether AR nuclear translocation also was atten-
-treated
are sho
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the absence of DHT, AR was confined predominantly to
the cytosol at comparable levels in both PAGE4 and
vector:LNCaP cells. However, after 1 hour of treatment
with DHT (when total AR protein levels remain compara-
ble between PAGE4 and vector:LNCaPs; see Supple-
mental Figure S5, C and D, at http://ajp.amjpathol.org),
nuclear AR levels increased 14.5-fold in vector:LNCaP
cells but were increased only 8.1-fold in PAGE4:LNCaPs
(1.8-fold; P  0.008; Figure 4, E and F). Under these
conditions, nuclear and cytosolic PAGE4 levels were not
altered significantly in the presence of DHT relative to
mock-treated cells (Figure 4E and data not shown). Col-
lectively, these data suggest that PAGE4 may impair AR
activity by attenuating AR phosphorylation and subse-
quently transcriptional activity, perhaps as an indirect
consequence of reduced AR nuclear translocation.
Attenuation of CR-PCa Xenograft Development
of PAGE4-Expressing PCa Cells
To investigate the significance of increased PAGE4 in
PCa (Figure 1) on tumor development and progression to
CR-PCa, PAGE4 and vector:LNCaP xenografts were es-
tablished in sham-castrated or castrated animals. In in-
tact mice, there was no significant difference in vector or
PAGE4:LNCaP xenografts with respect to tumor inci-
dence or volume (Figure 5, A and B). In agreement with
the earlier-described in vitro observations, PSA mRNA
and protein levels were significantly lower in PAGE4 ver-
Figure 4. Ligand-mediated AR nuclear translocation and phosphorylation ar
at serine 81 (A) or serine 213 (C) in vector and PAGE4:LNCaP#8 stimulated fo
(100 ng/mL) subsequently was added to existing media as indicated for a
vector:LNCaPs treated as indicated were incubated with lambda phosphatase
in A and C, respectively, relative to mock-treated vector control normalized
and cytosolic extracts from vector and PAGE4:LNCaP cells stimulated for 1
reloaded for longer exposure (5) enabling detection of nuclear PAGE4 (l
extracts prepared as in F from four independent experiments relative to mock
fractions) or lamin B (nuclear fractions). A, C, and E: Representative imagessus vector:LNCaP xenografts from sham-castrated ani-mals (Figure 5, C and D). Thus, despite attenuation of AR
in PAGE4:LNCaPs in vivo, tumorigenicity was not altered
in androgen-replete animals, probably owing to residual
AR activity because serum PSA still was detectable in
mice harboring PAGE4:LNCaP xenografts (2.0  0.7
ng/mL compared with 8.2  3.2 ng/mL in vector control
mice; P  0.04).
In castrated animals the tumor incidence was reduced
markedly by PAGE4 compared with vector control (Fig-
ure 5A). Initially, growth of the PAGE4:LNCaP tumors that
successfully developed was retarded significantly rela-
tive to the corresponding vector:LNCaP tumors (Figure
5B). After day 43, however, PAGE4:LNCaP tumors in
castrated mice underwent a marked growth surge,
reaching a mean volume comparable with their vector
control counterparts by day 57 (Figure 5B). Consistent
with progression to CR-PCa, AR and PSA mRNA and
protein levels were increased significantly in vector:
LNCaP tumors from castrated hosts relative to intact an-
imals (Figure 5, C and D). Similar up-regulation of AR and
PSA also was observed in PAGE4:LNCaP xenografts in
castrated mice, in contrast to AR inhibition in intact hosts
with PAGE4:LNCaP tumors (Figure 5, C and D), raising
the possibility that AR inhibition was subverted in these
successful PAGE4:LNCaP tumors. Consistently, although
unchanged at the mRNA level (not shown), PAGE4 pro-
tein levels were reduced in PAGE4:LNCaP tumors from
castrated animals compared with the co-harvested and
parallel-stained PAGE4:LNCaP tumors from sham-cas-
ated in PAGE4-expressing PCa cells. Immunoblotting of AR phosphorylated
rs with 10 nmol/L DHT () or vehicle equivalent (). For pSer213-AR, IGF-1
hours. Membranes were stripped and reprobed for total AR. Lysates from
oading as specificity control. B and D: Densitometric quantification of assays
otal AR (n  4). E: Immunoblotting with the indicated antibodies in nuclear
ith 10 nmol/L DHT () or vehicle equivalent (). Nuclear fractions were
o panels). F: Mean fold-change in AR densitometric intensity (SEM) in
vector control and normalized against lactate dehydrogenase (LDH, cytosolic
wn. B, D, and F: NS, not significant where P  0.05, *P  0.05, **P  0.01.e attenu
r 24 hou
further 4
before l
against t
hour w
ower twtrated hosts (Figure 5D).
sham-c
up. B an
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Status in PCa Clinical Specimens
By using a second independently stained TMA (ad-
vanced PCa TMA), we investigated whether PAGE4 lev-
els were associated with AR inhibition and progression to
advanced PCa in clinical specimens. Epithelial PAGE4
levels did not differ between hormone-naive PCa or CR-
PCa (see Supplemental Table S2 at http://ajp.amjpathol.
Figure 5. PAGE4 inhibits PCa xenograft development in androgen-depleted
Materials and Methods (n  17 mice per subgroup). A: Maximal tumor inciden
the indicated interval after inoculation. C: AR and PSA quantitative PCR in vecto
fold-change in expression SEM is shown relative to vector:LNCaP tumors from
processed in parallel. Images are representative of four tumors for each subgro
Table 2. PAGE4 Inversely Correlates with AR Status in Clinical P
Total AR*
Coefficient‡ P value
PAGE4
Hormone-naive PCa 0.16 0.0162
n  253 (n  236)
CR-PCa 0.13 0.0394
n  271 (n  248)
*Spot-by-spot analysis of epithelial PAGE4 immunohistochemistry stainin
†Comparison of serum PSA with PAGE4 immunohistochemistry scorein cases in which multiple spots were derived from a single patient biopsy spec
‡Values represent Spearman  correlation coefficients. Numbers in parenthesorg) and correlated neither with Gleason pattern nor pro-
liferation index (see Supplemental Tables S3 and S4 at
http://ajp.amjpathol.org). However, PAGE4 levels in-
versely correlated with total AR and pAR-Ser213 levels in
both hormone-naive PCa and CR-PCa with the inverse
correlation more strongly associated with hormone-naive
PCa (Table 2). Unfortunately, the reagents to address
pAR-Ser81 by IHC are lacking to date. Epithelial PAGE4
levels also inversely correlated with serum PSA in hor-
enografts from vector and PAGE4:LNCaP#8 were established as described in
ssed as the percentage of animals inoculated. B: Mean tumor volume  SEM at
GE4:LNCaP tumors harvested at day 63 from sham or castrated animals. Mean
astrated hosts (n 6). D: IHC of the indicated xenografts isolated at day 63 and
d C: NS, not significant where P  0.05, *P  0.05, and **P  0.01.
pSer213-AR* Serum PSA†
oefficient‡ P value Coefficient‡ P value
0.32 0.001 0.32 0.0034
n  212) (n  81)
0.18 0.006 0.19 0.121
n  246) (n  67)
ity with immunostaining levels of total AR and AR phosphorylated at Ser213.
the mean epithelial PAGE4 staining intensity score per biopsy specimenhosts. X
ce expre
r and PACa
C
(
(
g intens
s usingimen.
es denote sample number (n) for which both parameters were available.
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AJP October 2012, Vol. 181, No. 4mone-naive PCa (P  0.003; Table 2) but not in CR-PCa,
where PSA and PAGE4 levels showed an inverse but
nonsignificant trend (Table 2).
PAGE4 Levels Correlate with and Predict
Survival of Patients with Hormone-Naive PCa
Epithelial PAGE4 levels were analyzed with respect to
overall patient survival after TURP for local advanced
obstructive PCa. In CR-PCa, PAGE4 was not associated
with patient survival (P 0.8851). In hormone-naive PCa,
however, median survival of patients with tumors ex-
pressing high PAGE4 levels was 8.2 years (95% CI, 3.4 to
10.6) compared with 3.1 years (95% CI, 2.4 to 4.3) for
patients with tumors expressing negative/low levels of
PAGE4 (P  0.0096; Figure 6). In univariate analyses,
significant associations with hormone-naive patient sur-
vival were also observed for non-metastatic versus met-
astatic PCa (cM stage M0/M1, respectively), patient age
at TURP (cut-off  median), and Gleason pattern (Table
3). A multivariate analysis with the same parameters re-
vealed that high epithelial PAGE4 levels significantly pre-
dicted patient survival independently of Gleason pattern,
age, and cM stage (Table 3).
Figure 6. PAGE4 levels correlate with survival of patients with hormone-
naive PCa. Overall survival of patients with hormone-naive PCa after TURP
for local advanced obstructive PCa stratified for high versus negative/low
(neg/low) epithelial PAGE4 levels on the advanced PCa TMA (third quartile
of mean epithelial PAGE4 intensity was set as the cut-off level).
Table 3. PAGE4 Levels Are an Independent Predictor of Surviva
Parameter
Univariate
P value Hazard
cM 0.030* 1.5
Gleason pattern 0.005* 1.6
Age at surgery 0.003* 1.3
High PAGE4 0.009* 0.6
Univariate and multivariate analyses assessed by log-rank test or Cox
to hormone-naive PCa patient survival. Cut-off scores were set as M0 ver
obstructive PCa, and high epithelial PAGE4 staining intensity on the advan
PAGE4 intensity.
*P  0.05.Discussion
This study aimed to investigate the function of PAGE4, a
prostate-associated member of CTAs, and whether
PAGE4 dysregulation may play a role in PCa develop-
ment/progression. Collectively, in vitro and in vivo studies
herein indicate that signaling by AR and structurally re-
lated GR are attenuated in PAGE4-expressing cells, find-
ings consistent with the spatial restriction of PAGE4 to
steroidogenic tissues and with observations that intrinsi-
cally disordered proteins, including AR/GR, often are in-
volved in regulatory processes and cell signaling.25 At-
tenuation of AR/GR is unlikely to be a nonspecific artifact
of PAGE4 overexpression because (i) no effect on pro-
gesterone receptor activity (which also is related closely
to AR/GR) was observed on PAGE4 overexpression, (ii)
attenuated proliferation was observed in PAGE4-ex-
pressing AR LNCaP cells but not AR PC3 cells, (iii) AR
activity was unaltered in parallel-generated LNCaP sub-
lines overexpressing Dickkopf homolog 3, (iv) attenuation
of total/phospho-AR levels in PAGE4-expressing cells in
vitro similarly was observed in clinical specimens, and (v)
PAGE4 silencing in JEG3 cells (the only cell line identified
that expresses detectable protein levels of endogenous
PAGE4) potentiated endogenous GR activity, a finding
analogous to attenuated GR activity in COS7 cells on
PAGE4 overexpression. The structural and functional
similarity of GR with AR was exploited as the only means,
to our knowledge, of examining the effect of endogenous
PAGE4 knockdown on steroid hormone receptor signal-
ing. Further investigation into the significance of dysregu-
lated epithelial PAGE4 with respect to GR signaling in
PCa development/progression will be the subject of fu-
ture investigations.
Despite very low PAGE4 mRNA levels (our observa-
tions and that of G. Jenster, unpublished data), a recent
study reported detectable levels of endogenous PAGE4
protein in LNCaP cells, siRNA-mediated silencing that
induced apoptosis, and attenuated xenograft growth in
intact mice, whereas PAGE4 overexpression in HEK293T
and CWR22rv1 cells (both strongly GR) enhanced pro-
liferation.22 On the basis of data herein, it is possible that
enhanced proliferation on PAGE4 overexpression in
these cell lines reflects attenuation of antiproliferative,
pro-apoptotic GR signaling. Supportively, PAGE4 over-
tients with Hormone-Naive PCa
Multivariate
95% CI
P valueLower Upper
0.82 2.92 0.173
1.04 2.80 0.033*
0.96 1.80 0.087
0.45 0.95 0.024*
ional hazard ratio, respectively, for the indicated parameters with respect
for cM tumor stage, median patient age after TURP for local advanced
a TMA with the cut-off value set as the third quartile of the mean epitheliall for Pa
ratio
5
8
2
7
proport
sus M1
ced PC
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cell proliferation at day 3, although this was not significant
by day 5 (see Supplemental Figure 4C at http://ajp.
amjpathol.org). We were unable to detect endogenous
PAGE4 in LNCaP or other PCa cell lines using commer-
cial polyclonal or our in-house developed monoclonal
PAGE4 antibodies (Figure 3A), which show high speci-
ficity by signal quenching with blocking but not nonblock-
ing PAGE4 peptides (see Supplemental Figure S1 at
http://ajp.amjpathol.org). It also may be noted that the
authors of the aforementioned study22 previously identi-
fied PAGE4 protein in rat prostate,46 an unexpected ob-
servation because many CTAs, including PAGE4, lack
identifiable orthologs in rodent genomes.47 Thus, it is
possible that apoptosis induction by PAGE4 siRNAs in
PCa cell lines22 that express little or no detectable
PAGE4 may represent off-target effects. Supportively,
PAGE4 siRNAs had no significant effect on PSA mRNA
levels in wild-type LNCaP cells (our observation, not
shown). However, it also is plausible that very low basal
levels of PAGE4 are required to maintain cell viability,
whereas at increased concentrations (as observed in
high-grade PIN/localized PCa and mimicked in PAGE4:
LNCaPs) PAGE4, as an intrinsically disordered protein,
may engage in low affinity but specific protein-protein
interactions to modulate AR/GR activity.
PAGE4 expression was associated with impaired li-
gand-induced AR nuclear translocation, reduced phos-
phorylation at Ser81 and Ser213, and decreased AR sta-
bility. Consistently, total/pSer213-AR levels inversely
correlated with PAGE4 levels in clinical PCa. AR phos-
phorylation at Ser81 and Ser213 is directly mechanisti-
cally linked to AR stabilization and activity, the former
regulating AR in a promoter-specific manner37–39 and
likely accounting for AR attenuation at selective andro-
gen-responsive genes in PAGE4:LNCaPs. This is consis-
tent with studies showing that cis-acting AR regulators
confer promoter specificity of androgen signaling.11–16
However, AR phosphorylation at Ser81 is temporally
slower than the kinetics of nuclear import, whereas
Ser213 phosphorylation is rapid but apparently confined
to the nucleus.34,45 These observations, together with the
absence of PAGE4 sequence homology to known phos-
phatase or enzyme domains, suggest that impaired AR
phosphorylation, stabilization, and activity are likely
downstream consequences of attenuated nuclear trans-
location.
Precisely how PAGE4 attenuates AR nuclear translo-
cation remains to be determined. In the absence of an-
drogens, AR is sequestered in the cytoplasm via associ-
ation with multiprotein complexes of chaperones.9 On
ligand binding, AR undergoes a conformational change
resulting in the sequential loss of chaperones and un-
masking of the nuclear localization signal resulting in AR
nuclear translocation. Although PAGE4 is present in the
nucleus, a large fraction localizes to the cytosol, both in
vitro and in vivo. Thus, it is plausible that PAGE4 may
directly sequester the AR in the cytoplasm. However,
co-immunoprecipitation experiments failed to identify an
interaction between PAGE4 and AR (not shown), al-
though it cannot be excluded that as an intrinsically dis-ordered protein, PAGE4 interacts with AR in a specific,
but weak and/or transient, manner. Future studies thus
will focus on identifying PAGE4-interacting partners and
whether PAGE4 associates with AR kinases/phosphata-
ses or proteins known to modulate AR subcellular local-
ization, for example, heat shock protein chaperones,
phosphatase and tensin homolog deleted on chromo-
some 10, p21-activated kinase 6, and protein interacting
with amyloid precursor protein tail 1 (PAT1/ARA67).48–50
Up-regulation of epithelial PAGE4 in high-grade PIN
possibly reflects increased epigenetic remodeling and/or
transforming growth factor-1 production, changes that
are apparent in PIN and induce PAGE4mRNA in prostatic
epithelial cells in vitro17,51,52 (and data not shown). In
localized PCa and metastases, epithelial PAGE4 levels
subsequently were decreased. This is the first study re-
porting dysregulation of PAGE4 at the protein level during
PCa development/progression and is in agreement with
mRNA-based studies.53–57 Given that PAGE4 appears to
attenuate AR in a promoter-selective manner, we hypoth-
esize that increased PAGE4 in PIN may result in attenu-
ated AR signaling, favoring tumor initiation. It should be
noted that although established tumors are AR-depen-
dent, epithelial AR can suppress or promote tumorigen-
esis depending on the cancer-initiating signal.58,59 AR
regulates distinct transcriptional programs during PCa
development/progression owing, at least in part, to dys-
regulation of AR coregulators.11–16,60,61 Thus, the subse-
quent down-regulation of epithelial PAGE4 in localized
PCa and metastases may facilitate AR reactivation and
transcriptional programs required for progression to le-
thal advanced PCa. This hypothesis is supported by the
following observations: i) PAGE4 impaired the develop-
ment of CR-PCa xenografts; ii) the few CR-PCa xeno-
grafts that did establish, showed posttranscriptional
PAGE4 silencing; iii) PAGE4 levels inversely correlated
with AR status in clinical PCa; and iv) low PAGE4 levels
correlated with decreased patient survival in hormone-
naive PCa. Such promoter-specific regulation of AR by
PAGE4 and the distinct AR transcriptional program in
PCa versus CR-PCa also may explain why PAGE4 im-
paired xenograft development in androgen-depleted but
not replete animals.
In contrast to impaired development of CR-PCa xeno-
grafts by PAGE4:LNCaPs and reduced survival of hor-
mone-naive patients with high PAGE4-expressing tu-
mors, epithelial PAGE4 protein levels did not correlate
with serum PSA or patient survival in clinical CR-PCa,
even though total/pSer213-AR levels inversely correlated
with epithelial PAGE4, albeit less strongly than in hor-
mone-naive PCa. Interestingly, PAGE4 protein levels
were comparable in CR-PCa and hormone-naive PCa,
suggesting that in these clinical CR-PCa specimens AR
bypass pathways were major determinants of tumor pro-
gression (eg, BCL2, cyclooxygenase-2, or neuroendo-
crine differentiation)62 and/or PAGE4-mediated AR inhi-
bition may have been subverted, perhaps via altered
PAGE4 posttranslational modification(s) required for AR
inhibition, but not detected by the current monoclonal
antibody. Further studies are underway to investigate this
possibility and to determine whether restoring PAGE4-
PAGE4 Positivity Predicts Hormone-Naive PCa 1453
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patients with CR-PCa.
Loss of PAGE4 correlated with poor overall survival in
hormone-naive PCa patients. Contemporary survival data
for hormone-naive PCa are somewhat higher than those
herein, but typically derive from asymptomatic patients
with low-grade PCa, whereas the hormone-naive PCa
patient cohort in the current study underwent TURP for
local advanced obstructive PCa. In support of our find-
ings, PAGE4 mRNA levels recently were reported to be
lower in biochemical recurrent PCa, but although posi-
tively associated with delayed biochemical recurrence,
PAGE4 mRNA levels were not independent predictors of
biochemical recurrence.57 At the protein level, however,
multivariate analyses showed that PAGE4 positivity pre-
dicted favorable survival of patients with hormone-naive
PCa independently of Gleason pattern, age at surgery,
and cM tumor stage. Thus, PAGE4 represents a potential
independent prognostic molecular marker to identify pa-
tients at risk of developing lethal advanced PCa.
In summary, these data are consistent with an AR/GR
repressor function of PAGE4, which, when dysregulated,
may play a functional role during tumor progression to
advanced lethal PCa, and highlight the potential value of
PAGE4 as a prognostic/therapeutic target.
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